In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVN – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $3.27.
Okunewitch covers the Healthcare sector, focusing on stocks such as Lexaria Bioscience, Mediwound, and Citius Pharmaceuticals. According to TipRanks, Okunewitch has an average return of -24.8% and a 18.46% success rate on recommended stocks.
Longeveron has an analyst consensus of Moderate Buy, with a price target consensus of $13.25.
See Insiders’ Hot Stocks on TipRanks >>
Based on Longeveron’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $93 thousand and a GAAP net loss of $5.63 million. In comparison, last year the company earned a revenue of $466 thousand and had a GAAP net loss of $5.62 million
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Read More on LGVN:
- Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
- Longeveron reports Q2 EPS (27c), consensus (25c)
- Longeveron announces surpassing 50% enrollment threshold for study of lomecel-B
- Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome
- EmergingGrowth.com to host a virtual conference
